Trimi Health Review: $99 Is $1,188 Paid Once, Up Front

$175 a month for compounded semaglutide and $235 for compounded tirzepatide if you pay month to month. The $99 and $125 in the advertising are the annual plans, billed $1,188 and $1,500 in a single charge. Two tiers sit in between: six months at $720 ($120/mo) or $1,050 ($175/mo), and a quarter at $435 ($145/mo) or $597 ($199/mo). Trimi publishes all eight figures itself — on the treatment pages, on /promo, in the structured data and in its llms.txt — and they agree everywhere. Read on August 9, 2026.

Because Trimi's own savings labels only work if it is. Each block tier is captioned with what you save: $90 on the quarter, $330 on six months, $912 on the year. Those are exactly $175 × 3 − $435, $175 × 6 − $720, and $175 × 12 − $1,188. The arithmetic closes to the dollar on all three, which is the cleanest confirmation of a base rate you can get from a marketing page. It does not close on tirzepatide — see below.

Because two of them are measured against a price Trimi does not sell. The quarterly tier is fine: "Save $108" is exactly $235 × 3 − $597. But "Save $540" on the six-month plan needs a monthly rate of $265, and "Save $1,680" on the annual needs the same $265. Against the real $235 the savings are $360 and $1,320 — still substantial, but $180 and $360 less than advertised. The block totals themselves, $1,050 and $1,500, are consistent on every page and in the structured data, so it is the savings captions that are stale rather than the prices.

Only before a clinician signs your prescription — and on the annual plan, you have already paid $1,188 by then. Trimi's Refund Policy is unusually clear about where the line sits: "You can cancel any time before your prescription is issued… full refund, no fees, no questions," and after it, "whether the medication is being compounded, has been compounded, or has shipped, the order cannot be canceled and is non-refundable." A patient a provider declines to treat gets 100% back automatically. There is also a six-month money-back promise, which refunds plan fees if you complete six continuous months as prescribed, log a starting and six-month weight in the portal, and still have not lost weight — one claim per patient, requested within 30 days of the six-month mark.

The pricing page says no, four times over: "No enrollment, consultation, shipping, or cancellation fees", with the medication, clinician consultation, dose management, 24/7 messaging, syringes, alcohol swabs and cold-chain shipping all inside the plan price. One thing does not fit. The Refund Policy, describing what a declined patient gets back, itemises "the provider consultation fee, the medication fee, and any plan deposit" — three charges the pricing page says are not separately levied. Nothing on the site shows any of them being charged, so the likeliest explanation is boilerplate, but it is the kind of loose thread worth asking about before you pay for a year.

No, and Trimi is emphatic about it: the plan price is "flat at every dose rather than rising as you titrate." That covers the whole tirzepatide ladder, 2.5 mg through 15 mg, and the semaglutide range up to 2.4 mg. It is the single most consequential thing a GLP-1 seller can promise, because the dose you start on is not the dose you spend most of the year on, and a provider that re-prices at each step turns an advertised figure into something closer to a deposit.

VialsRx, a Texas 503A community sterile compounding pharmacy, licence #35264, which Trimi says fulfils the majority of its prescriptions, with GreenwichRx as the secondary 503A partner. Trimi publishes the licence number, the pharmacy class and even the pharmacist-in-charge, which is more than almost anyone else in this category does — most say "a licensed U.S. pharmacy" and stop. Both pharmacies were screened against FDA's warning-letter index on August 9, 2026 and neither holds a letter. Clinical care runs through a separate partner, Arora Health, whose network Trimi says is licensed in all 50 states and D.C.

Yes, on the evidence available. Trimi publishes a page for every state and one for the District of Columbia — 51 in its own sitemap — and quotes the same $99 and $125 on each. There is no exclusion list anywhere on the site, and the coverage is credited to Arora Health's clinician licensure across all 50 states plus D.C. Trimi also says eligibility is verified during the assessment before any payment is taken, so a state problem would surface before your card is charged rather than after.

No, and neither does either pharmacy. Screened on August 9, 2026 against FDA's live warning-letter index: "trimihealth", "trytrimi", "Arora Health", "VialsRx" and "GreenwichRx" all return nothing. The spaced searches return a handful of letters to other companies — Revive Rx Pharmacy, Carolina Infusion, Biotek India — none of which names Trimi, Arora Health or either pharmacy in the company column, so nothing has been filed here on a resemblance. Worth being clear about what that proves: no letter means no letter, not that anything has been inspected and approved.

Start monthly, whatever the arithmetic says. The annual plan saves $912 on semaglutide and $1,320 on tirzepatide, which is real money, but it front-loads the entire year into one payment that stops being refundable the moment a clinician signs your script — and a meaningful proportion of people stop GLP-1 therapy in the first two months because of side effects. $175 for one month buys you the information that $1,188 does not: whether you tolerate the drug. If you get to month three and it is working, the quarterly and six-month tiers are still there, and the six-month plan at $720 captures most of the annual discount for half the exposure.